Intelligence desk

Products

Signal Tracker Data Platform Data Enrichment API

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
RiboNova, Inc. logo — Focused on Mitochondrial Disease & other serious rare diseas...

RiboNova, Inc.

Focused on Mitochondrial Disease & other serious rare diseases. R007 is our P2 ready asset, we also have tRNA discovery.

Founded 2011 United States Wynnewood, United States 7 employees Series Unknown Total: $25.00K Biotechnology, Pharmaceutical

General Information

Company Name RiboNova, Inc.
Founded Year 2011
Location United States Wynnewood, United States +1
Employees 7
Industries Biotechnology, Pharmaceutical
Funding Stage Series Unknown
Social

Get notified when RiboNova, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About RiboNova, Inc.

RiboNova, Inc. is a biopharmaceutical company founded in 2011, with a primary focus on developing treatments for mitochondrial disease and other serious rare diseases. The company's flagship asset, R007, is a Phase-2 ready small molecule drug designed to address all forms of genetically-confirmed mitochondrial disease. Additionally, RiboNova has a tRNA discovery program that targets defective transfer RNAs, offering potential treatment options for a range of human diseases. The burden of mitochondrial disease is severe, with an estimated 75,000 people affected in the US, and high morbidity and mortality rates, especially in children. Despite the significant impact on patients and the healthcare system, there are currently no FDA-approved drugs for mitochondrial disease. RiboNova's approach is notable for its innovative focus on targeting the underlying genetic causes of the disease, using DNA sequencing and a proprietary drug discovery platform to develop precision medicines. One of the company's key strengths lies in its commitment to addressing the unmet needs of patients suffering from mitochondrial diseases. RiboNova's strategic positioning within the Lankenau Institute for Medical Research near Philadelphia also provides access to valuable resources and expertise in the biopharmaceutical field. With a $25.00K Venture Round investment in March 2019, the company is positioned for further growth and potential breakthroughs in the treatment of mitochondrial and other rare diseases.

Taxonomy: biopharmaceutical company, rare diseases, mitochondrial disease, treatment, drug discovery, precision medicine, tRNA, genetic diagnosis, DNA sequencing, ribonucleic acid, clinical biomarkers, therapeutic targets, translational medicine, Phase-2 ready drug

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $25.00K - 01 Mar 2019
Seed Round Unknown 1
BioAdvance
23 Feb 2016

RiboNova, Inc. Alternatives & Competitors

RiboNova, Inc. vs
Expansion Therapeutics
Expansion Therapeutics United States

Bringing transformative therapies to patients with severe RNA-mediated diseases.

Series Unknown
29 employees
Biotechnology, Health Care
RiboNova, Inc. vs
Saverna Therapeutics AG
Saverna Therapeutics AG Switzerland

Saverna Therapeutics aims to discover highly active, selective and cell-permeable molecules to targe...

Series Unknown
4 employees
AI, Health and Wellness
RiboNova, Inc. vs
Tango Therapeutics
Tango Therapeutics United States

Targeting tumor suppressor loss to unmask vulnerabilities for the next generation of precision medic...

Post Ipo Equity
157 employees
Biotechnology, Health Care
Also compare with: RiboNova, Inc. vs HemoShear Therapeutics HemoShear Therapeutics

FAQ About RiboNova, Inc.

Focused on Mitochondrial Disease & other serious rare diseases. R007 is our P2 ready asset, we also have tRNA discovery.
RiboNova, Inc. was founded in 2011.
RiboNova, Inc. is headquartered in Wynnewood, United States.
RiboNova, Inc. operates in the following industries: Biotechnology, Pharmaceutical.
RiboNova, Inc. has approximately 7 employees.
RiboNova, Inc. has completed 2 funding rounds, raising a total of $25.00K. The latest funding stage is Series Unknown.
Top alternatives and competitors to RiboNova, Inc. include Expansion Therapeutics, Saverna Therapeutics AG, Tango Therapeutics, Nimbus Therapeutics, Visterra Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
RiboNova, Inc. and Expansion Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors RiboNova, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy